Frontiers in Nutrition Review Proposes Peripheral-to-Central Resolution-Biology Framework for Eicosapentaenoic Acid

A narrative review proposes evaluating eicosapentaenoic acid (EPA) through a peripheral-to-central resolution-biology framework to clarify clinical heterogeneity and establish rigorous biological boundaries in brain aging and mood research.

A structured critical narrative review published in Frontiers in Nutrition on August 7, 2026, evaluated the therapeutic and mechanistic roles of eicosapentaenoic acid (EPA) in emotional well-being and brain aging.

The author, Qihui Peng of Foresight Life Science, introduced a peripheral-to-central resolution-biology framework. This model suggests that EPA-derived specialized pro-resolving mediators (SPMs), such as E-series resolvins, can influence brain-relevant outcomes through peripheral inflammatory resolution, endothelial signaling, and blood-brain barrier (BBB) pathways, rather than relying solely on the bulk accumulation of EPA in brain tissue.

The review explicitly differentiated isolated EPA-predominant clinical evidence from broader, mixed omega-3, fish-intake, or biomarker-status studies, characterizing the latter as hypothesis-generating rather than proof of EPA-specific efficacy.

To resolve historical trial inconsistencies, the paper examined how variations in EPA dose, chemical formulation, background diet, placebo choice, and patient baseline profiles (such as baseline omega-3 status and low-grade inflammation) act as primary sources of heterogeneity.

To prevent precision-nutrition frameworks from becoming unfalsifiable post hoc, the review defined explicit biological contexts for validation and specified that the proposed framework would be weakened if future pre-stratified trials with verified exposure consistently report null effects.

Broad 'omega-3' terminology frequently obscures clinical and mechanistic differences between EPA and docosahexaenoic acid (DHA). While DHA serves primary neural structural roles, EPA is primarily relevant to peripheral immune regulation and active inflammatory resolution.

The framework provides a biological explanation for prominent null results in unstratified prevention trials, such as the VITAL-DEP and VITAL-Cog ancillary studies, which evaluated generic marine omega-3 doses in broad cohorts that did not target low baseline fatty acid status or elevated inflammatory phenotypes.

The active resolution of inflammation via specialized pro-resolving mediators (SPMs) represents a conceptual shift away from passive anti-inflammatory suppression, introducing a measurable metabolic sequence that can be monitored during clinical development.

The emphasis on biomarker-informed patient enrollment is likely to shift clinical trial designs for longevity therapeutics and advanced nutritional supplements toward using the Omega-3 Index and high-sensitivity C-reactive protein (hs-CRP) as mandatory enrichment criteria.

A transition toward purified, high-dose EPA-predominant formulations with verified blood-level exposures may accelerate the decline of generic fish-oil blends in the premium longevity market, favoring products with scientifically validated, phenotype-aligned target populations.

The initiation of preregistered, adequately powered clinical trials utilizing pure or EPA-predominant formulations that restrict enrollment to individuals with verified low baseline omega-3 status (e.g., Omega-3 Index below 4%) and elevated low-grade inflammation (e.g., hs-CRP above 3 mg/L).

Direct translational validation of the peripheral-to-central pathway in humans using advanced neuroimaging endpoints, such as arterial-spin-labeling MRI for cerebral blood flow and PET-indexed neuroinflammation markers.